Nuclear Medicine Market worth $21.01 billion by 2030
The report "Nuclear Medicine Market by Type [SPECT (Tc-99m, I-123, Ga-67), PET (F-18), Alpha Emitters, Beta Emitters (Y-90, Lu-177), Brachytherapy], Application (Oncology, Cardiology, Neurology), Procedure, End User (Imaging Center, Hospital), and Region – Global Forecast to 2030” is projected to grow from USD 10.41 billion in 2025 and to reach USD 21.01 billion by 2030, at a Compound Annual Growth Rate (CAGR) of 15.1% during the forecast period.
Browse 450 market data Tables and 50 Figures spread through 342 Pages and in-depth TOC on "Nuclear Medicine Market by Type [SPECT (Tc-99m, I-123, Ga-67), PET (F-18), Alpha Emitters, Beta Emitters (Y-90, Lu-177), Brachytherapy], Application (Oncology, Cardiology, Neurology), Procedure, End User (Imaging Center, Hospital), and Region – Global Forecast to 2030”
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/radiopharmaceuticals-market-417.html
The nuclear medicine market is growing due to the growing acceptance of molecular imaging and theranostics and progress in radiopharmaceutical development, including novel PET and SPECT tracers and targeted radionuclide therapies. Additionally, advancements in imaging systems, automation of radiopharmacy processes, and advances in the capabilities of producing and supplying isotopes, among others, are also contributing to the growth of the market. Moreover, the increasing focus on precision and personalised medicine, increased investment in the healthcare infrastructure, and favourable regulatory approvals for the new radiopharmaceuticals are accelerating the acceptance of the latest technologies in hospitals and in imaging diagnostics, which is also spurring market growth.
“The diagnostic nuclear medicine segment accounted for a larger share than the therapeutic nuclear medicine segment in 2024.”
The diagnostic nuclear medicine segment accounted for a larger share than the therapeutic nuclear medicine segment in 2024. The dominance of the segment is because of the widespread adoption of PET and SPECT imaging for accurate and non-invasive detection and monitoring of diseases. Additionally, the constant improvement of the radiotracer development and imaging technologies has improved diagnostic accuracy and clinical utility. Moreover, increased access to diagnostic radiopharmaceuticals, improved imaging facilities, and the increasing merging of nuclear imaging and advanced analytics have also enhanced the dominance of this segment.
“The hospitals segment is projected to be the fastest-growing segment during the forecast period.”
By end user, the hospitals segment is projected to be the fastest-growing market during the forecast period. This projection is due to the rising investments in advanced imaging facilities and the development of an in-house nuclear medicine division. The radiopharmacy of hospitals is being enhanced with the use of integrated diagnostic services that can improve workflow efficiency and clinical decision-making, and also stimulate further segment growth.
“North America is projected to dominate the nuclear medicine market during the forecast period.”
North America is projected to dominate the nuclear medicine market during the forecast period. This projection has been made due to the presence of a well-established radiopharmaceutical manufacturing and distribution ecosystem in the region. North America has strong investments in healthcare infrastructure, extensive access to nuclear medicine services in hospitals and diagnostic centers, and a well-developed regulatory framework supporting innovation. It also has the presence of major radiopharmaceutical manufacturers and nuclear pharmacy networks, along with the continuous approval of new diagnostic and therapeutic radioisotopes. All these factors create a positive impact on the growth of the region as a market.
Key Players
The key players operating in the nuclear medicine market include GE HealthCare (US), Cardinal Health (US), Curium (France), Bayer AG (Germany), Lantheus Holdings, Inc. (US), Novartis AG (Switzerland), Jubilant Pharmova Limited (India), Bracco Imaging S.P.A (Italy), Pharmalogic Holdings Corp. (US), NTP Radioisotopes SOC Ltd. (South Africa), Nordion Inc. (Canada), Siemens Healthineers AG (Germany), NorthStar Medical Radiosiotopes, LLC (US), Eckert & Ziegler (Germany), Isotope JSC (Russia), Global Medical Solutions (US), Telix Pharmaceuticals Limited (Australia), PDRadiopharma Inc. (Japan), ITM Isotope Technologies Munich SE (Germany), BWX Technologies Inc. (US), SHINE Technologies, LLC (US), Isotopia (Israel), Institutes of Isotopes (Hungary), China Isotope & Radiation Corporation (China), and IRE Elit (Turkey).
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Nuclear Medicine Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
